Deca-Durabolin is an injectable anabolic preparation. The decanoate ester gives the preparation a duration of action of about 3 weeks after injection.
Nandrolone is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor-binding studies. The low androgenicity of nandrolone is confirmed in clinical use.
In humans, Deca-Durabolin has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. In women with disseminated mammary carcinoma, Deca-Durabolin has been reported to produce objective regressions for many months. Furthermore, Deca-Durabolin has nitrogen-saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists eg, during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Deca-Durabolin serves as a supportive adjunct to specific therapies and dietary measures as well as parenteral nutrition.
Androgenic effects (eg, virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C-17α-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.
Pharmacokinetics: Nandrolone decanoate is slowly released from the injection site into the blood with a half-life of 6 days. In the blood, the ester is rapidly hydrolysed to nandrolone with a half-life of ≤1 hr. The half-life for the combined process of hydrolysis of nandrolone decanoate and of distribution and elimination of nandrolone is 4.3 hrs. Nandrolone is metabolised by the liver. 19-norandrosterone, 19-noretiocholanolone and 19-norepiandrosterone have been identified as metabolites in the urine. It is not known whether these metabolites display a pharmacological action.